Alopecia Areata (Eli Lilly and Company Study)
This study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.
Trial available at the following locations:
Maryland,
View Trial
Maryland,